Skip to main content
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Publisher: Bentham Science Publishers

More about this publication?
Volume 21, Number 10, 2014

Articles

Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
pp. 1171-1187(17)
Authors: Garcia, A.M.; Redondo, M.; Martinez, A.; Gil, C.

Favourites:
ADD

Updating the Use of Synthetic Peptides as Inhibitors of HIV-1 Entry
pp. 1188-1200(13)
Authors: Jose Gomara, Maria; Haro, Isabel

Favourites:
ADD

Oxidative Stress in Traumatic Brain Injury
pp. 1201-1211(11)
Authors: Rodriguez-Rodriguez, Ana; Jose Egea-Guerrero, Juan; Murillo-Cabezas, Francisco; Carrillo-Vico, Antonio

Favourites:
ADD

Neuritin, A Neurotrophic Factor in Nervous System Physiology
pp. 1212-1219(8)
Authors: Zhou, S.; Zhou, J.

Favourites:
ADD

Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents
pp. 1220-1230(11)
Authors: Hu, Chunqi; Li, Xin; Wang, Wei; Zhang, Ruoyu; Deng, Liping

Favourites:
ADD

FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
pp. 1231-1246(16)
Authors: Carbajo-Pescador, S.; Mauriz, J.L.; GarcĂ­a-Palomo, A.; Gonzalez-Gallego, J.

Favourites:
ADD

Conjugation of Peptides to Antisense Interleukin-6 Via Click Chemistry
pp. 1247-1254(8)
Authors: Wang, Chang-Fang; Auriola, Seppo; Hirvonen, Jouni; A. Santos, Helder

Favourites:
ADD

Adipocytes Contribute to Resistance of Human Melanoma Cells to Chemotherapy and Targeted Therapy
pp. 1255-1267(13)
Authors: Chi, M.; Chen, J.; Ye, Y.; Tseng, Hsin-Yi; Lai, F.; Tay, K.H.; Jin, L.; Guo, S.T.; Jiang, C.C.; Zhang, X.D.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content